Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma

Immune checkpoint therapy has resulted in minimal clinical response in many pediatric cancers. We sought to understand the influence of immune checkpoint inhibition using anti-PD-1 and anti-CTLA-4 antibodies individually, in combination, and after chemotherapy on immune responses in minimal and esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirinbak, Soheila, Chan, Randall Y., Shahani, Shilpa, Muthugounder, Sakunthala, Kennedy, Rebekah, Hung, Long T., Fernandez, G. Esteban, Hadjidaniel, Michael D., Moghimi, Babak, Sheard, Michael A., Epstein, Alan L., Fabbri, Muller, Shimada, Hiroyuki, Asgharzadeh, Shahab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801125/
https://www.ncbi.nlm.nih.gov/pubmed/33489468
http://dx.doi.org/10.1080/2162402X.2020.1838140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801125/
https://www.ncbi.nlm.nih.gov/pubmed/33489468
http://dx.doi.org/10.1080/2162402X.2020.1838140

Ejemplares similares